Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles

被引:4
|
作者
Purwar, Mansi [1 ]
Pokorski, Jonathan K. [2 ,3 ,6 ]
Singh, Pranveer [1 ,7 ]
Bhattacharyya, Sanchari [1 ]
Arendt, Heather [4 ]
DeStefano, Joanne [4 ]
La Branche, Celia C. [5 ]
Montefiori, David C. [5 ]
Finn, M. G. [2 ,3 ,8 ]
Varadarajan, Raghavan [1 ]
机构
[1] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India
[2] Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA
[4] Int AIDS Vaccine Initiat, Brooklyn, NY 11226 USA
[5] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[6] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA
[7] Mahatma Gandhi Cent Univ Bihar, Dept Zool, Motihari 845401, Bihar, India
[8] Georgia Inst Technol, Sch Chem & Biochem, 901 Atlantic Dr, Atlanta, GA 30332 USA
基金
美国国家卫生研究院;
关键词
Protein stability; Immune focusing; Neutralizing antibodies; Vaccine; Nanoparticles; OUTER-DOMAIN; DISULFIDE BONDS; NEUTRALIZING ANTIBODIES; TYPE-1; VACCINE; CD4; CORE; SITE; GLYCOSYLATION; GLYCOPROTEIN;
D O I
10.1016/j.vaccine.2018.07.032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The broadly neutralizing antibody against HIV-1, b12, binds to the CD4 binding site (CD4bs) on the outer domain (OD) of the gp120 subunit of HIV-1 Env. We have previously reported the design of an E. coli expressed fragment of HIV-1 gp120, b122a, containing about 70% of the b12 epitope with the idea of focusing the immune response to this structure. Since the b122a structure was found to be only partially folded, as assessed by circular dichroism and protease resistance, we attempted to stabilize it by the introduction of additional disulfide bonds. One such mutant, b122a1-b showed increased stability and bound b12 with 30-fold greater affinity as compared to b122a. Various b122a and OD fragment proteins were displayed on the surface of Qp virus-like particles. Sera raised against these particles in six-month long rabbit immunization studies could neutralize Tier1 viruses across different subtypes with the best results observed with b122a1-b displayed particles. Significantly higher amounts of antibodies directed towards the CD4bs were also elicited by particles displaying b122a1-b. This study highlights the ability of fragment immunogens to focus the antibody response to the conserved CD4bs of HIV-1. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6345 / 6353
页数:9
相关论文
共 50 条
  • [21] Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
    Wang, Shixia
    Chou, Te-hui
    Hackett, Anthony
    Efros, Veronica
    Wang, Yan
    Han, Dong
    Wallace, Aaron
    Chen, Yuxin
    Hu, Guangnan
    Liu, Shuying
    Clapham, Paul
    Arthos, James
    Montefiori, David
    Lu, Shan
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (12) : 2996 - 3009
  • [22] Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein
    Liang, XP
    Munshi, S
    Shendure, J
    Mark, G
    Davies, ME
    Freed, DC
    Montefiori, DC
    Shiver, JW
    VACCINE, 1999, 17 (22) : 2862 - 2872
  • [23] Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity
    Guo, Wenjin
    Cleveland, Brad
    Davenport, Thaddeus M.
    Lee, Kelly K.
    Hu, Shiu-Lok
    PROTEIN EXPRESSION AND PURIFICATION, 2013, 90 (01) : 34 - 39
  • [24] Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles
    Chapman, Rosamund
    van Diepen, Michiel
    Galant, Shireen
    Kruse, Elizabeth
    Margolin, Emmanuel
    Ximba, Phindile
    Hermanus, Tandile
    Moore, Penny
    Douglass, Nicola
    Williamson, Anna-Lise
    Rybicki, Edward
    VACCINES, 2020, 8 (01)
  • [25] Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection
    Raska, Milan
    Czernekova, Lydie
    Moldoveanu, Zina
    Zachova, Katerina
    Elliott, Matt C.
    Novak, Zdenek
    Hall, Stacy
    Hoelscher, Michael
    Maboko, Leonard
    Brown, Rhubell
    Smith, Phillip D.
    Mestecky, Jiri
    Novak, Jan
    AIDS RESEARCH AND THERAPY, 2014, 11
  • [26] Production of HIV-1-based virus-like particles for vaccination: achievements and limits
    Cervera, Laura
    Godia, Francesc
    Tarres-Freixas, Ferran
    Aguilar-Gurrieri, Carmen
    Carrillo, Jorge
    Blanco, Julia
    Gutierrez-Granados, Sonia
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2019, 103 (18) : 7367 - 7384
  • [27] Proteomic Characterization of Influenza H5N1 Virus-like Particles and Their Protective Immunogenicity
    Song, Jae-Min
    Choi, Chi-Won
    Kwon, Sang-Oh
    Compans, Richard W.
    Kang, Sang-Moo
    Kim, Seung Il
    JOURNAL OF PROTEOME RESEARCH, 2011, 10 (08) : 3450 - 3459
  • [28] Virus-Like Particles Carrying HIV-1 Env with a Modulated Glycan Composition
    Kaevitser, G. A.
    Samokhvalov, E. I.
    Scheblyakov, D. V.
    Gintsburg, A. L.
    Vzorov, A. N.
    MOLECULAR BIOLOGY, 2024, 58 (04) : 763 - 772
  • [29] How promising are HIV-1-based virus-like particles for medical applications
    Martins, Sofia A.
    Santos, Joana
    Silva, Ruben D. M.
    Rosa, Catia
    Cabo Verde, Sandra
    Correia, Joao D. G.
    Melo, Rita
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [30] Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles
    Perez-Saucedo, David
    Castro-Perea, Nancy Vanessa
    Ruiz-Cruz, Antonio
    Bustos-Jaimes, Ismael
    Viveros-Rogel, Monica
    Huerta-Hernandez, Leonor
    Moreno-Fierros, Leticia
    VACCINE, 2025, 45